Ageless Pep Academy Clinical Education · Licensed Prescribers

Semax

Semax

⚠️ Structural Separation Notice

The Ageless Pep Academy is a clinical education property independent from any commerce operation. Any references in this profile to Ageless Peps product SKUs, pricing, or the agelesspeps.com domain are for completeness and transparency; they are not endorsements and do not form part of the clinical education content. Clinicians are responsible for independent verification of any product sourcing decision. The Academy's Medical Director provides editorial oversight only and does not endorse commercial products.

Synthetic heptapeptide ACTH(4-10) analog with Pro-Gly-Pro C-terminal extension; potent BDNF/NGF upregulator and neuroprotective nootropic without corticotropic activity.

Quick Facts

Property Value
Also Known As ACTH(4-10) analog, Met-Glu-His-Phe-Pro-Gly-Pro, Semax 0.1%
Category Cognitive / Neuroprotection
Sequence MEHFPGP (7 amino acids)
Molecular Weight ~813 Da
Molecular Formula C39H53N9O10
PubChem CID 68816
Administration Intranasal (primary), SubQ
Typical Dose Range 200-600 mcg intranasal, 1-2x daily
Half-Life ~30 minutes
Storage Lyophilized: -20C, stable 1-2 years. Reconstituted/solution: 2-8C, use within 2-4 weeks, protect from light.
FDA Status Not FDA-approved. Approved in Russia as a nootropic/neuroprotective drug (stroke, ADHD, optic nerve atrophy).
WADA Status Prohibited under S0 (Non-Approved Substances)

Mechanism of Action

Semax is a synthetic analog of the adrenocorticotropic hormone fragment ACTH(4-10) stabilized by the addition of a Pro-Gly-Pro (PGP) tripeptide at the C-terminus, which confers resistance to enzymatic degradation and extends its biological half-life. Critically, the structural modifications eliminate all corticotropic (adrenal-stimulating) activity while preserving and enhancing the nootropic and neuroprotective properties inherent in the ACTH(4-7) core sequence (PMID-16996037).

The primary mechanism underlying Semax's cognitive and neuroprotective effects is the rapid, region-specific upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF). Studies demonstrate that intranasal administration of Semax produces significant increases in BDNF mRNA expression in the hippocampus, frontal cortex, and basal forebrain within 30 minutes of administration, with effects persisting for several hours (PMID-14556513, PMID-16635254). The temporal dynamics of BDNF and NGF induction vary by brain region, suggesting Semax engages distinct transcriptional programs in different neuroanatomical areas rather than triggering a uniform global response (PMID-19662538).

Semax exerts its effects partly through the melanocortin receptor system (MC4R/MC5R), consistent with its ACTH-derived structure, though its receptor binding profile differs from native melanocortins. This melanocortin pathway engagement contributes to both its nootropic signaling and its anti-inflammatory properties. Additionally, Semax modulates dopamine and serotonin neurotransmission, increasing dopamine turnover in the prefrontal cortex and regulating serotonergic signaling in limbic structures, providing a neurochemical basis for its effects on attention, executive function, and mood stabilization (PMID-39442746).

In the context of cerebral ischemia, Semax activates neurotrophin gene transcription programs that are suppressed following stroke, promoting neurovascular repair and reducing infarct volume in animal models. Genome-wide transcriptional analysis has demonstrated that Semax modulates the expression of genes involved in inflammation, apoptosis, and neurotransmission in ischemic brain tissue, providing a molecular basis for its neuroprotective actions (PMID-19633950, PMID-24661604).

Key Research Areas

  1. BDNF and Neurotrophin Upregulation — Semax rapidly increases BDNF and NGF gene expression in hippocampus, cortex, and retina, with region-specific temporal dynamics. Direct binding to BDNF protein in the basal forebrain has been demonstrated (PMID-14556513, PMID-16635254, PMID-17353092, PMID-19662538).

  2. Stroke and Cerebral Ischemia Neuroprotection — In both animal models and Russian clinical use, Semax demonstrates neuroprotective effects in ischemic stroke, activating survival gene programs and reducing neurological deficit scores. Genome-wide transcriptomic analysis reveals modulation of inflammatory and apoptotic pathways (PMID-19633950, PMID-24661604, PMID-29798983).

  3. Human Functional Neuroimaging — fMRI studies in healthy human volunteers demonstrate that Semax alters functional connectivity in brain networks associated with cognition and attention, providing direct human neuroimaging evidence for its central effects (PMID-32342318).

  4. Antidepressant and Antistress Activity — Semax exhibits antidepressant-like effects in animal models of stress, with mechanisms linked to BDNF-TrkB pathway modulation and monoamine regulation (PMID-39442746).

  5. Cognitive Enhancement and Nootropic Effects — Russian clinical approval for ADHD and cognitive deficits is supported by preclinical evidence of improved learning and memory, likely mediated by BDNF-dependent synaptic plasticity (PMID-16996037).

  6. Broader Peptide Therapeutics — Semax is included in comprehensive reviews of therapeutic peptides, highlighting its place within the broader peptide medicine landscape (PMID-41490200).

Evidence Level Summary

Evidence Type Count Notes
Human RCTs 0 No English-language RCTs; Russian approval based on trials published in Russian
Human observational / neuroimaging 1 fMRI functional connectivity study in healthy volunteers (PMID-32342318)
Animal in vivo 5 BDNF/NGF expression, ischemia models, antidepressant models
In vitro 0 —
Systematic reviews 0 —
Narrative reviews 5 Including ACTH analog mechanism reviews, therapeutic peptide reviews

Note on evidence: Semax is approved in Russia for acute ischemic stroke, ADHD, and optic nerve atrophy. However, the majority of Russian clinical trial data (including Phase III trials supporting approval) is published in Russian-language journals and is not fully accessible or indexed in English-language databases. The English-language evidence base is predominantly preclinical.

Clinical Applications

  • Cognitive Enhancement — BDNF-mediated enhancement of synaptic plasticity, attention, and executive function
  • Neuroprotection — Neurotrophin upregulation protects against neurodegenerative processes
  • Stroke Recovery — Neuroprotective gene activation in ischemic tissue; clinical use in Russia for acute stroke
  • Depression — Antidepressant effects via BDNF-TrkB and monoamine modulation
  • Anxiety — Adjunctive anxiolytic effects, especially when combined with Selank

Protocols Using This Peptide

Ageless Peps Products

  • AP-Semax-Vial — Semax Vial, $64, intranasal/SubQ

Dosing Reference

Research Dosing Ranges (from literature)

Route Dose Range Frequency Duration Source
Intranasal 200-600 mcg 1-2x daily 2-4 weeks on / 2 weeks off Russian clinical protocols
Intranasal 300-600 mcg Single dose Acute cognitive demand Practitioner guides
SubQ 100-300 mcg 1x daily 2-4 weeks Practitioner guides

Cycling

Standard cycling is 2 weeks on / 2 weeks off. Some Russian protocols extend to 3-4 weeks on for stroke recovery applications. Cycling rationale: while tolerance has not been formally demonstrated, periodic breaks are recommended to maintain neurotrophin receptor sensitivity and prevent potential downregulation of BDNF response.

Contraindications & Safety

  • Contraindications: Active seizure disorders (theoretical concern due to neurotrophin modulation and increased neuronal excitability). Acute psychosis (dopaminergic enhancement may worsen symptoms).
  • Common side effects: Nasal irritation/dryness with intranasal use; mild stimulant-like effects at higher doses (dose-dependent).
  • Drug interactions: Theoretical potentiation of dopaminergic and serotonergic medications. No formally documented drug interactions in English literature.
  • Pregnancy/nursing: Insufficient data; not recommended.
  • Special populations: Russian clinical use data suggests good tolerability in elderly stroke patients. No specific data on renal/hepatic impairment or pediatric populations in English literature.

Translation limitation: Many Russian studies supporting clinical use are not fully accessible in English. Practitioners should be aware that the English-language evidence base underrepresents the clinical data supporting Semax's approved indications.

Cancer Considerations

LIKELY SAFE — No cancer-relevant pathways. No cancer-specific studies exist for Semax. Its mechanism (BDNF/NGF upregulation, ACTH fragment without corticotropic activity) does not involve angiogenesis, EMT, growth factor receptor activation, or telomerase modulation. BDNF has been studied in cancer contexts with mixed results, but at the doses and CNS-focused action of intranasal Semax, systemic tumor promotion is unlikely. Acceptable for cognitive/neuroprotective goals in cancer patients if oncologist approves.

Synergistic Combinations

  • Selank + Semax — Complementary nootropic-anxiolytic "flow state" stack. Semax provides cognitive drive via BDNF/dopamine; Selank provides anxiolysis via GABA-A modulation. Both share the PGP stabilization motif and intranasal route. Human fMRI data supports distinct but complementary effects on brain functional connectivity (PMID-32342318).
  • Dihexa + Semax — Synergistic memory enhancement via complementary neurotrophic pathways (HGF/MET + BDNF/TrkB).
  • PE-22-88 + Semax — Neurotrophin amplification stack for BDNF-focused cognitive protocols.

Related Research

PMID Title Year Study Type
PMID-14556513 – The heptapeptide SEMAX stimulates BDNF expression in differe The heptapeptide SEMAX stimulates BDNF expression in different areas of the rat brain in vivo 2003 Animal in vivo
PMID-16635254 – Semax Binds and Increases BDNF in Rat Basal Forebrain Semax Binds and Increases BDNF in Rat Basal Forebrain 2006 Animal in vivo
PMID-16996037 – Semax, an analog of ACTH(4-10) with cognitive effects, regul Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus 2007 Animal in vivo
PMID-17353092 – Neurotrophin Gene Expression Under Semax Neurotrophin Gene Expression Under Semax 2007 Animal in vivo
PMID-19633950 – Semax Activates Neurotrophin Transcription After Cerebral Ischemia Semax Activates Neurotrophin Transcription After Cerebral Ischemia 2009 Animal in vivo
PMID-19662538 – Comparison of the temporary dynamics of NGF and BDNF gene ex Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action 2009 Narrative review
PMID-24661604 – Semax Genome-Wide Transcriptional Analysis in Focal Ischemia Semax Genome-Wide Transcriptional Analysis in Focal Ischemia 2014 Animal in vivo
PMID-29798983 – [The efficacy of semax in the tretament of patients at diffe The efficacy of semax in the treatment of patients at different stages of ischemic stroke 2018 Narrative review
PMID-32342318 – Functional Connectomic Approach to Semax and Selank Effects Functional Connectomic Approach to Semax and Selank Effects 2020 Human neuroimaging
PMID-39442746 – Semax Antidepressant and Antistress Effects Semax Antidepressant and Antistress Effects 2024 Narrative review
PMID-41490200 – Therapeutic Peptides in Orthopaedics Applications, Challeng Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions 2025 Narrative review

References

Related

#peptide #cognitive #intranasal #subq